Cited by 199Alzheimer's disease research and treatmentsCalpain Protease Function and RegulationDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains

Open access

Tseng, Huang-Chun, Zhou, Ying, Shen, Yong, Tsai, Li-Huei·2002·FEBS Letters

DOI 10.1016/s0014-5793(02)02934-4

Open this paper in CoChat — free account Open PDF

Abstract

P25, a calpain cleavage product of the cyclin‐dependent kinase 5 (Cdk5) activator p35, causes prolonged activation of Cdk5. Although p25 has been shown to accumulate in brains of patients with Alzheimer's disease (AD), it is not known whether p25 accumulation in AD is brain region‐specific. We analyzed the amounts of p25 and p35 in human autopsy samples from multiple brain regions including frontal cortex, inferior parietal cortex and hippocampus using immunoblotting assays. Our results show that the p25–p35 indices are higher in AD than in the control groups in all three brain regions. The most significant difference in p25–p35 indices between AD and control groups is in the frontal cortex. No significant difference in calpain activity between AD and control groups is observed, indicating that postmortem calpain activation cannot account for the elevation of p25/p35 ratios in AD brains. Our results support the notion that p25 accumulation deregulates Cdk5 activity in AD brains, and the deregulated Cdk5 activity may contribute to the pathogenesis of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0014-5793(02)02934-4

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L. R., Nikolić, M., de la Monte, S. M., Dikkes, P., & Tsai, L. (1999) · Nature · doi:10.1038/45159 · Cited by 1,541
Self-citation
Neurotoxicity induces cleavage of p35 to p25 by calpain
Lee, M.-S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., & Tsai, L. (2000) · Nature · doi:10.1038/35012636 · Cited by 1,057
Self-citation
Proline-directed and non-proline-directed phosphorylation of PHF-tau
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., & Ihara, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.823 · Cited by 557
Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system
Tsai, L., Takahashi, T., Caviness, V. S., & Harlow, E. (1993) · Development · doi:10.1242/dev.119.4.1029 · Cited by 457
Self-citation
Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25
Kusakawa, G.-I., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T., & Hisanaga, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m907757199 · Cited by 381
An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator
Tang, D., Yeung, J., Lee, K., Matsushita, M., Matsui, H., Tomizawa, K., Hatase, O., & Wang, J. H.-C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26897 · Cited by 340
Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A. B., Kowsz, K. P., McCarthy, S. A., Coskran, T., Carlo, A. A., Seymour, P. A., Burkhardt, J. E., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040577797 · Cited by 339
Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death
Alvarez, A. R., Toro, R., Cáceres, A., & Maccioni, R. B. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01279-x · Cited by 228
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration
Pei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226

Show all 20 references

Research works printed but not linked: 1

Snedecor G.W. and Cochran W.G. (1989) Statistical Methods 8th edn. Iowa State University Press Ames IA.

Sorted by citations

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Reelin and brain development
Tissir, F., & Goffinet, A. M. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1113 · Cited by 767
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles
Cruz, J. C., Tseng, H.-C., Goldman, J. A., Shih, H., & Tsai, L.-H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00627-5 · Cited by 609
Self-citation
Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo
Noble, W. J., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J. L., Gaynor, K., LaFrancois, J. J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 511
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
Cyclin-Dependent Kinases in Brain Development and Disease
Su, S. C., & Tsai, L. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154023 · Cited by 318
Self-citation
Oxidative Stress in Neurodegeneration
Shukla, V., Mishra, S. K., & Pant, H. C. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/572634 · Cited by 303
Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory
Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., & Tsai, L.-H. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.033 · Cited by 277
Self-citation
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies
Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N. F., Greengard, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701055104 · Cited by 274
The Role of Cdk5 in Alzheimer’s Disease
Liu, S., Wang, C., Jiang, T., Tan, L., Xing, A., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9369-x · Cited by 274
Cdk5 deregulation in the pathogenesis of Alzheimer's disease
Cruz, J. C., & Tsai, L.-H. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.07.001 · Cited by 258
Self-citation
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Calcium signaling in Alzheimer's disease & therapies
Tong, B. C., Wu, A. J., Li, M., & Cheung, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 243
Transcriptional Regulation of β-Secretase by p25/cdk5 Leads to Enhanced Amyloidogenic Processing
Wen, Y., Yu, W. H., Maloney, B., Bailey, J. A., Ma, J., Marié, I., Maurin, T., Wang, L., Figueroa, H. Y., Herman, M., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.02.024 · Cited by 201
Cdk5 activity in the brain – multiple paths of regulation
Shah, K., & Lahiri, D. K. (2014) · Journal of Cell Science · doi:10.1242/jcs.147553 · Cited by 205
Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice
Piedrahita, D., Hernández, I., Tobon, A., Fedorov, D., Obara, B., Manjunath, B. S., Boudreau, R. L., Davidson, B. L., LaFerla, F. M., Gallego-Gómez, J. C., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3637-10.2010 · Cited by 188
1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β
Kunick, C., Lauenroth, K., Leost, M., Meijer, L., & Lemcke, T. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.062 · Cited by 180
The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer’s disease-like tau phosphorylation
Jämsä, A., Hasslund, K., Cowburn, R. F., Bäckström, A., & Vasänge, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.075 · Cited by 171
A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease
Cruz, J. C., & Tsai, L. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.05.002 · Cited by 173
Self-citation
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
Wen, Y., Yang, S.-H., Liu, R., Perez, E. J., Brun-Zinkernagel, A. M., Koulen, P., & Simpkins, J. W. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.011 · Cited by 162
Three decades of Cdk5
Pao, P., & Tsai, L. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00774-y · Cited by 154
Self-citation
Cyclin‐dependent kinase‐5 in neurodegeneration
Shelton, S. B., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02328.x · Cited by 146
Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity
Wilkaniec, A., Gąssowska-Dobrowolska, M., Strawski, M., Adamczyk, A., & Czapski, G. A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1027-y · Cited by 133
A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice
Shukla, V., Zheng, Y., Mishra, S. K., Amin, N. D., Steiner, J. P., Grant, P. G., Kesavapany, S., & Pant, H. C. (2012) · The FASEB Journal · doi:10.1096/fj.12-217497 · Cited by 134
Cdk5/p25-Induced Cytosolic PLA2-Mediated Lysophosphatidylcholine Production Regulates Neuroinflammation and Triggers Neurodegeneration
Sundaram, J. R., Chan, E. S., Poore, C. P., Pareek, T. K., Cheong, W. F., Shui, G., Tang, N., Low, C., Wenk, M. R., & Kesavapany, S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5177-11.2012 · Cited by 129
Cdk5: Multitasking between physiological and pathological conditions
Lopes, J. P., & Agostinho, P. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.006 · Cited by 134
Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction
Sun, K., de Pablo, Y., Vincent, F., & Shah, K. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05616.x · Cited by 124
The impact of loneliness and social isolation on the development of cognitive decline and Alzheimer’s Disease
Ren, Y. L., Savadlou, A., Park, S., Siska, P., Epp, J. R., & Sargin, D. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101061 · Cited by 137
Cdk5, a therapeutic target for Alzheimer's disease?
Tsai, L., Lee, M.-S., & Cruz, J. C. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.019 · Cited by 122
Self-citation
Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E
Saavedra, L., Mohamed, A., Ma, V., Kar, S., & de Chaves, E. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701823200 · Cited by 118
Cyclin-Dependent Kinase 5 Mediates Neurotoxin-Induced Degradation of the Transcription Factor Myocyte Enhancer Factor 2
Tang, X., Wang, X., Gong, X., Tong, M., Park, D. S., Xia, Z., & Mao, Z. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1331-05.2005 · Cited by 121
Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an Apolipoprotein E receptor/disabled‐1/glycogen synthase kinase‐3β cascade
Ohkubo, N., Lee, Y., Morishima, A., Terashima, T., Kikkawa, S., Tohyama, M., Sakanaka, M., Tanaka, J., Maeda, N., Vitek, M. P., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0434fje · Cited by 117
Regulation and role of cyclin‐dependent kinase activity in neuronal survival and death
Hisanaga, S., & Endo, R. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07050.x · Cited by 120
Tau as a therapeutic target in neurodegenerative disease
Himmelstein, D. S., Ward, S., Lancia, J. K., Patterson, K. R., & Binder, L. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.001 · Cited by 122
Collapsin Response Mediator Proteins Regulate Neuronal Development and Plasticity by Switching Their Phosphorylation Status
Yamashita, N., & Goshima, Y. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8242-4 · Cited by 115
c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice
Cancino, G. I., Perez de Arce, K., Castro, P. U., Toledo, E. M., von Bernhardi, R., & Alvarez, A. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.007 · Cited by 110
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders
Eira, J., Silva, C. S., Sousa, M. M., & Liz, M. A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.007 · Cited by 109
Cdk5: One of the links between senile plaques and neurofibrillary tangles?
Lee, M.-S., & Tsai, L. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5207 · Cited by 104
Self-citation
Cell Cycle Deficits in Neurodegenerative Disorders: Uncovering Molecular Mechanisms to Drive Innovative Therapeutic Development
Joseph, C., Mangani, A. S., Gupta, V. B., Chitranshi, N., Shen, T., Dheer, Y., Devaraj, K. B., Mirzaei, M., You, Y., Graham, S. L., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.0923 · Cited by 101
MAP1B phosphorylation is differentially regulated by Cdk5/p35, Cdk5/p25, and JNK
Kawauchi, T., Chihama, K., Nishimura, Y. V., Nabeshima, Y., & Hoshino, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.132 · Cited by 98
Alzheimer?s disease: the impact of age-related changes in reproductive hormones
Simpkins, J. W., Yang, S., Wen, Y., & Singh, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4382-2 · Cited by 96
Spatial Learning Impairment, Enhanced CDK5/p35 Activity, and Downregulation of NMDA Receptor Expression in Transgenic Mice Expressing Tau-Tubulin Kinase 1
Sato, S., Xu, J., Okuyama, S., Martinez, L. B., Walsh, S. M., Jacobsen, M. T., Swan, R. J., Schlautman, J. D., Ciborowski, P. S., & Ikezu, T. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3417-08.2008 · Cited by 94
Inhibition of JNK by a Peptide Inhibitor Reduces Traumatic Brain Injury–Induced Tauopathy in Transgenic Mice
Tran, H., Sanchez, L., & Brody, D. L. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182456aed · Cited by 93
The Regulation of Cyclin-Dependent Kinase 5 Activity through the Metabolism of p35 or p39 Cdk5 Activator
Hisanaga, S., & Saito, T. (2003) · Neurosignals · doi:10.1159/000074624 · Cited by 95
The cell cycle as a therapeutic target for Alzheimer's disease
Neve, R. L., & McPhie, D. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.005 · Cited by 92
A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation
Zheng, Y., Amin, N. D., Hu, Y., Rudrabhatla, P., Shukla, V., Kanungo, J., Kesavapany, S., Grant, P. G., Albers, W., & Pant, H. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134643 · Cited by 97
Amyloid‐β‐induced toxicity of primary neurons is dependent upon differentiation‐associated increases in tau and cyclin‐dependent kinase 5 expression
Liu, T., Perry, G. L., Chan, H. W., Verdile, G., Martins, R. N., Smith, M. A., & Atwood, C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02196.x · Cited by 85
Cdk5: mediator of neuronal death and survival
Cheung, Z. H., & Ip, N. Y. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.117 · Cited by 85
Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression
Angelo, M., Plattner, F., Irvine, E. E., & Giese, K. P. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02746.x · Cited by 82
Deregulated Cdk5 Triggers Aberrant Activation of Cell Cycle Kinases and Phosphatases Inducing Neuronal Death
Chang, K., Vincent, F., & Shah, K. (2012) · Journal of Cell Science · doi:10.1242/jcs.108183 · Cited by 85
Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles
Tandon, A., Yu, W. H., Wang, L., Rogaeva, E. A., Sato, C., Chishti, M. A., Kawarai, T., Hasegawa, H., Chen, F., Davies, P., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01865.x · Cited by 83
COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo
Tong, Y., Xu, Y., Scearce-Levie, K. A., Ptáček, L. J., & Fu, Y. (2009) · Neurogenetics · doi:10.1007/s10048-009-0201-5 · Cited by 78
Glutathione‐S‐transferase P1 is a critical regulator of Cdk5 kinase activity
Sun, K., Chang, K., Clawson, S., Ghosh, S., Mirzaei, H., Regnier, F. E., & Shah, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07343.x · Cited by 77
Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration
Duan, Y., Dong, S., Gu, F., Hu, Y., & Zhao, Z. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-24 · Cited by 80
The cellular basis of dendrite pathology in neurodegenerative diseases
Kweon, J. H., Kim, S., & Lee, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.1.131 · Cited by 73
Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses
Wilkaniec, A., Czapski, G. A., & Adamczyk, A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13365 · Cited by 69
β-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals
Wu, H., Kuo, P.-C., Wang, Y.-T., Lin, H.-T., Roe, A. D., Wang, B. Y., Han, C., Hyman, B. T., Chen, Y., & Tai, H. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly059 · Cited by 72
Role of Cyclin-Dependent Kinase 5 in the Neurodegenerative Process Triggered by Amyloid-Beta and Prion Peptides: Implications for Alzheimer’s Disease and Prion-Related Encephalopathies
Lopes, J. P., Oliveira, C. R., & Agostinho, P. M. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9224-3 · Cited by 65
Cyclin-Dependent Kinase 5 in Amyotrophic Lateral Sclerosis
Nguyen, M. D., & Julien, J. (2003) · Neurosignals · doi:10.1159/000074623 · Cited by 61
Early oxidative stress and DNA damage in Aβ-burdened hippocampal neurons in an Alzheimer’s-like transgenic rat model
Foret, M. K., Orciani, C., Welikovitch, L. A., Huang, C., Cuello, A. C., & Carmo, S. D. (2024) · Communications Biology · doi:10.1038/s42003-024-06552-4 · Cited by 63
Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism
Sadleir, K. R., & Vassar, R. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333914 · Cited by 59
Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer’s Disease
Song, W.-J., Son, M.-Y., Lee, H.-W., Seo, H., Kim, J. H., & Chung, S.-H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136950 · Cited by 50
Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways
Hu, J.-P., Xie, J., Wang, C., Wang, T., Wang, X., Wang, S., Teng, W., & Wang, Z. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.03.006 · Cited by 60
Role of cdk5 in the Pathogenesis of Alzheimer’s Disease
Lau, L., & Ahlijanian, M. K. (2003) · Neurosignals · doi:10.1159/000074622 · Cited by 60
S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy
Amal, H., Gong, G., Gjoneska, E., Lewis, S. M., Wishnok, J. S., Tsai, L., & Tannenbaum, S. R. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0388-7 · Cited by 55
Self-citation
Activation of cyclin‐dependent kinase 5 by calpains contributes to human immunodeficiency virus‐induced neurotoxicity
Wáng, Y., White, M. G., Akay, C., Chodroff, R. A., Robinson, J., Lindl, K. A., Dichter, M. A., Qian, Y., Mao, Z., Kolson, D. L., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04746.x · Cited by 58
Altered regulation of tau phosphorylation in a mouse model of down syndrome aging
Sheppard, O., Plattner, F., Rubin, A. N., Slender, A., Linehan, J. M., Brandner, S., Tybulewicz, V. L. J., Fisher, E., & Wiseman, F. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.025 · Cited by 55
Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?
Luo, W., Rodina, A., & Chiosis, G. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s7 · Cited by 56
Cyclin-Dependent Kinase 5 in Neurofilament Function and Regulation
Kesavapany, S., Li, B.-S., & Pant, H. C. (2003) · Neurosignals · doi:10.1159/000074627 · Cited by 54
Cyclin‐dependent kinase 5 increases perikaryal neurofilament phosphorylation and inhibits neurofilament axonal transport in response to oxidative stress
SHEA, T. B., Zheng, Y., Ortiz, D., & Pant, H. C. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20099 · Cited by 55
p25/Cyclin‐dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum‐stressed neurons
Saito, T., Konno, T., Hosokawa, T., Asada, A., Ishiguro, K., & Hisanaga, S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04540.x · Cited by 53
Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization
Lapresa, R., Agulla, J., Sánchez‐Morán, I., Zamarreño, R., Prieto, E., Bolaños, J. P., & Almeida, Á. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.019 · Cited by 54
Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer’s disease
Katsel, P., Tan, W., Fam, P., Purohit, D. P., & Haroutunian, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068361 · Cited by 52
Enhanced Tau Phosphorylation in the Hippocampus of Mice Treated with 3,4-Methylenedioxymethamphetamine (“Ecstasy”)
Busceti, C. L., Biagioni, F., Riozzi, B., Battaglia, G., Storto, M., Cinque, C., Molinaro, G., Gradini, R., Caricasole, A., Canudas, A. M., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0159-08.2008 · Cited by 51
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro
Peterson, D. W., Ando, D. M., Taketa, D. A., Zhou, H., Dahlquist, F. W., & Lew, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912718107 · Cited by 51
SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration
Huang, T. Y., Zhao, Y., Jiang, L.-L., Li, X., Liu, Y., Sun, Y., Piña-Crespo, J. C., Zhu, B., Masliah, E., Willnow, T. E., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171413 · Cited by 50
Effect of conjugated linoleic acid, μ-calpain inhibitor, on pathogenesis of Alzheimer's disease
Lee, E., Eom, J.-E., Kim, H.-L., Baek, K. H., Jun, K.-Y., Kim, H., Lee, M., Mook‐Jung, I., & Kwon, Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.12.003 · Cited by 50
Long non‐coding RNA 00507/miRNA‐181c‐5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer's disease
Yan, Y., Yan, H., Teng, Y., Wang, Q., Yang, P., Zhang, L., Cheng, H., & Fu, S. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3268 · Cited by 49
Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons
Futatsugi, A., Utreras, E., Rudrabhatla, P., Jaffe, H., Pant, H. C., & Kulkarni, A. B. (2012) · Cell Cycle · doi:10.4161/cc.20009 · Cited by 50
Calcium Ions Stimulate the Hyperphosphorylation of Tau by Activating Microsomal Prostaglandin E Synthase 1
Cao, L., Guan, P.-P., Liang, Y.-Y., Huang, X., & Wang, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00108 · Cited by 42
Phosphoproteomic Analysis with a Solid-Phase Capture-Release-Tag Approach
Tseng, H.-C., Ovaa, H., Wei, N., Ploegh, H. L., & Tsai, L. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.05.012 · Cited by 43
Self-citation
Presenilin 1 in migration and morphogenesis in the central nervous system
Louvi, A., Sisodia, S. S., & Grove, E. A. (2004) · Development · doi:10.1242/dev.01191 · Cited by 42
Phosphorylation of FTDP-17 Mutant tau by Cyclin-dependent Kinase 5 Complexed with p35, p25, or p39
Sakaue, F., Saito, T., Satō, Y., Asada, A., Ishiguro, K., Hasegawa, M., & Hisanaga, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504792200 · Cited by 41
TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice
Shukla, V., Seo, J., Binukumar, B. K., Amin, N. D., Reddy, P. H., Grant, P. G., Kuntz, S., Kesavapany, S., Steiner, J. P., Mishra, S. K., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160916 · Cited by 40
Self-citation
Cyclin-Dependent Kinase 5–Dependent BAG3 Degradation Modulates Synaptic Protein Turnover
Zhou, J., Chow, H., Liu, Y., Wu, D., Shi, M., Li, J., Wen, L., Gao, Y., Chen, G., Zhuang, K., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.11.013 · Cited by 40
Sexual dimorphisms in the effect of low‐level p25 expression on synaptic plasticity and memory
Ris, L., Angelo, M., Plattner, F., Capron, B., Errington, M. L., Bliss, T. V. P., Godaux, E., & Giese, K.-P. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04137.x · Cited by 39
Yeast as a Model System to Study Tau Biology
Vos, A. D., Anandhakumar, J., den Brande, J. V., Verduyckt, M., Franssens, V., Winderickx, J., & Swinnen, E. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/428970 · Cited by 41
Cyclin-Dependent Kinase 5 Activator p25 Is Generated During Memory Formation and Is Reduced at an Early Stage in Alzheimer's Disease
Engmann, O., Hortobágyi, T., Thompson, A., Guadagno, J., Troakes, C., Soriano, S., Al‐Sarraj, S., Kim, Y. D., & Giese, K.-P. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.011 · Cited by 38
Knockout of p75 neurotrophin receptor attenuates the hyperphosphorylation of Tau in pR5 mouse model
Manucat-Tan, N. B., Shen, L.-L., Bobrovskaya, L., Al‐Hawwas, M., Zhou, F. H., Wang, Y., & Zhou, X. (2019) · Aging · doi:10.18632/aging.102202 · Cited by 36
Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease
Edward, A. M. I. (2005) · Frontiers in bioscience · doi:10.2741/1516 · Cited by 39
Phyto-Carbazole Alkaloids from the Rutaceae Family as Potential Protective Agents against Neurodegenerative Diseases
Tan, M. A., Sharma, N., & An, S. S. A. (2022) · Antioxidants · doi:10.3390/antiox11030493 · Cited by 38
A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases
Lace, G., Wharton, S. B., & Ince, P. G. (2007) · Clinical Neuropathology · doi:10.5414/npp26043 · Cited by 37
Alzheimer’s Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration
Durairajan, S. S. K., Selvarasu, K., Bera, M. R., Rajaram, K., Iyaswamy, A., & Li, M. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210906125318 · Cited by 36
Activation of latent cyclin‐dependent kinase 5 (Cdk5)–p35 complexes by membrane dissociation
Zhu, Y., Saito, T., Asada, A., Maékawa, S., & Hisanaga, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03301.x · Cited by 35
Partial Rescue of the p35−/− Brain Phenotype by Low Expression of a Neuronal-Specific Enolase p25 Transgene
Patzke, H., Maddineni, U., Ayala, R., Morabito, M. A., Volker, J., Dikkes, P., Ahlijanian, M. K., & Tsai, L. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02769.2003 · Cited by 35
Self-citation
Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease
Rademakers, R., Sleegers, K., Theuns, J., den Broeck, M. V., Kacem, S. B., Nilsson, L., Adolfsson, R., van Duijn, C. M., Broeckhoven, C. V., & Cruts, M. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.003 · Cited by 35

Authors: Tseng, H.-C., Zhou, Y., Shen, Y., & Tsai, L.-H.
Affiliations: Howard Hughes Medical Institute (US)
Banner Sun Health Research Institute (US)
Corresponding author: Tsai, Li-Huei
ORCID: Zhou, Ying
Shen, Yong
Tsai, Li-Huei
Venue: FEBS Letters
Publisher: Wiley
Published: 2002-06-18
Volume: 523
Issue: 1-3
Pages: 58-62
ISSN: 0014-5793 (ISSN-L)
1873-3468
DOI: 10.1016/s0014-5793(02)02934-4
OpenAlex: W2092765133
Cited by: 198
References: 20
Citations by year: 2026: 4 · 2025: 12 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 4 · 2017: 9 · 2016: 6 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 19
FWCI: 7.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: FEBS Letters (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
National Institutes of Health
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Calpain Protease Function and Regulation
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, cyclin-dependent kinase 5, p35, p25, calpain cleavage, brain region-specific expression, frontal cortex, hippocampus, inferior parietal cortex, postmortem brain
MeSH terms: Alzheimer Disease, Brain, Calpain, Frontal Lobe, Hippocampus, Humans, Nerve Tissue Proteins, Parietal Lobe, Postmortem Changes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks